Portola Pharmaceuticals Inc.'s Factor Xa inhibitor betrixaban's future in the EU is looking dicey after the EMA's CHMP issued a negative trend vote on the product's marketing application at its meeting this week. On the plus side, it also communicated a positive trend vote on the MAA for its universal Factor Xa inhibitor reversal agent, AndexXa (andexanet alfa), but this too represents a slight delay.
Betrixaban's negative trend vote means it is unlikely the committee will adopt a positive opinion on the company's MAA at...







